Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer

摘要: Purpose: Panitumumab, a fully human anti–epidermal growth factor receptor (EGFR) monoclonal antibody, is approved as monotherapy for the treatment of metastatic colorectal cancer. We evaluated association tumor EGFR expression levels with outcomes in patients chemorefractory Experimental Design: Two phase II, multicenter, single-arm, open-label studies enrolled tumors expressing low/negative (1-9%/ KRAS status were carried out. Results: A total 203 (Low/Negative EGFR) and 185 (High studies. The overall response rate was 5.7% [95% confidence interval (95% CI), 2.6-10.5] 4.2% CI, 1.6-9.0) high EGFR; at week 16 4% both (all partial responses). Median PFS times 8.1 weeks 7.1-12.6), 7.4-11.1), 7.3 7.1-7.6) negative, low, expression, respectively. OS longer wild-type than those mutant . As expected, most adverse events skin related. Conclusions: These confirm previous reports that are not associated efficacy an anti-EGFR antibody therapy should be limited to whose express Clin Cancer Res; 16(7); 2205–13. ©2010 AACR.